Syndax Pharmaceuticals (NASDAQ:SNDX) CMO Nicholas A.J. Botwood Sells 31,235 Shares

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CMO Nicholas A.J. Botwood sold 31,235 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $18.14, for a total value of $566,602.90. Following the transaction, the chief marketing officer owned 60,885 shares of the company’s stock, valued at $1,104,453.90. This trade represents a 33.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Nicholas A.J. Botwood also recently made the following trade(s):

• On Thursday, June 11th, Nicholas A.J. Botwood sold 34,280 shares of Syndax Pharmaceuticals stock. The stock was sold at an average price of $18.00, for a total value of $617,040.00.

Syndax Pharmaceuticals Trading Up 1.9%

Shares of SNDX traded up $0.34 during mid-day trading on Friday, reaching $18.25. 1,048,610 shares of the company were exchanged, compared to its average volume of 1,515,450. The stock has a market capitalization of $1.62 billion, a PE ratio of -6.54 and a beta of 0.38. Syndax Pharmaceuticals, Inc. has a 52 week low of $8.59 and a 52 week high of $25.59. The company has a debt-to-equity ratio of 8.26, a quick ratio of 5.06 and a current ratio of 5.47. The business has a 50 day simple moving average of $21.17 and a two-hundred day simple moving average of $21.24.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.11. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 256.65%. The company had revenue of $64.86 million for the quarter, compared to analyst estimates of $69.76 million. During the same period in the prior year, the firm posted ($0.98) EPS. The company’s quarterly revenue was up 224.3% on a year-over-year basis. On average, analysts predict that Syndax Pharmaceuticals, Inc. will post -1.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Syndax Pharmaceuticals by 21.2% during the 4th quarter. Vanguard Group Inc. now owns 6,230,334 shares of the company’s stock valued at $130,899,000 after acquiring an additional 1,091,717 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Syndax Pharmaceuticals by 3.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 5,695,375 shares of the company’s stock valued at $119,660,000 after acquiring an additional 208,941 shares during the period. State Street Corp lifted its position in shares of Syndax Pharmaceuticals by 19.3% during the 4th quarter. State Street Corp now owns 4,596,552 shares of the company’s stock valued at $96,574,000 after acquiring an additional 743,003 shares during the period. Bank of America Corp DE lifted its position in shares of Syndax Pharmaceuticals by 33.7% during the 2nd quarter. Bank of America Corp DE now owns 3,838,872 shares of the company’s stock valued at $35,951,000 after acquiring an additional 967,873 shares during the period. Finally, Kingdon Capital Management L.L.C. boosted its holdings in Syndax Pharmaceuticals by 19.0% in the third quarter. Kingdon Capital Management L.L.C. now owns 2,500,000 shares of the company’s stock worth $38,462,000 after acquiring an additional 400,000 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Mizuho decreased their price target on Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Syndax Pharmaceuticals in a research report on Friday. UBS Group reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Friday, March 27th. Finally, Citigroup boosted their price target on Syndax Pharmaceuticals from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $42.55.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.